psoriasis: An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
544 |
4. Check minimum number of eventsNone |
544 |
5. Include endpointsNone |
544 |
6. Filter based on genotype QC (FinnGen only) |
520 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L40
- Name in latin
- Psoriasis guttata
Similar endpoints
↥List of similar endpoints to
Guttate psoriasis
based on the number of shared cases.
Similar with more cases:
- Psoriasis
- Papulosquamous disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3699 | 2116 | 1568 |
| Only index persons | 3553 | 2064 | 1489 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.06 | 0.04 |
| Only index persons | 0.07 | 0.08 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 41.77 | 41.62 | 41.86 |
| Only index persons | 41.40 | 41.48 | 41.29 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 520 | 322 | 198 |
| Unadjusted period prevalence (%) | 0.11 | 0.11 | 0.09 |
| Median age at first event (years) | 47.69 | 45.53 | 51.21 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 544
- Matched controls
- 5440
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D05AX02
ATC
calcipotriol; topical
145.0
307.7
271
37
D05AX52
ATC
calcipotriol, combinations; topical
192.7
307.7
377
63
D07XC01
ATC
betamethasone; topical
24.4
307.7
310
280
L40.0
ICD-10 Finland
Psoriasis vulgaris
930.2
307.7
384
14
L40.4
ICD-10 Finland
Guttate psoriasis
4503599627370496.0
307.7
537
*
L40
ICD-10 Finland
Psoriasis
82.5
217.9
117
18
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
86.9
208.6
111
16
L04AX03
ATC
methotrexate; systemic
13.8
185.5
215
246
D07AC01
ATC
betamethasone; topical
13.3
173.7
433
1236
D05BB02
ATC
acitretin; oral
235.6
154.8
153
9
E000001, ,
ATC
8.6
143.7
293
647
D07AD01
ATC
clobetasol; topical
9.0
140.9
245
454
E0000UV, ,
ATC
12.0
140.8
452
1580
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
763.5
126.8
120
*
D05AX03
ATC
calcitriol; topical
255.8
121.1
120
6
D07AC13
ATC
mometasone; topical
6.8
111.7
325
973
D07AB08
ATC
desonide; topical
8.1
107.1
180
312
L40.9
ICD-10 Finland
Psoriasis, unspecified
185.3
103.3
105
7
L40.5
ICD-10 Finland
Arthropathic psoriasis
1116.9
98.2
93
*
D07AB02
ATC
hydrocortisone butyrate; topical
5.7
90.1
314
1057
TQW80
NOMESCO Finland
Local dermatologic skincare
19.0
85.5
70
42
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
7.9
82.1
130
207
E000002, ,
ATC
6.4
79.5
166
351
E000003, ,
ATC
10.4
76.6
92
104
D02AE01
ATC
carbamide; topical
8.0
68.3
104
157
M07.3
ICD-10 Finland
Other psoriatic arthropathies
345.2
61.7
61
*
D02AX
ATC
Other emollients and protectives
12.0
61.3
65
61
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
+∞
59.5
56
*
L01BA01
ATC
methotrexate; systemic
12.9
58.5
59
51
S91
ICPC
Psoriasis
94.4
54.1
59
7
L04AB04
ATC
adalimumab; parenteral
13.0
49.5
49
41
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.6
40.7
113
294
D05AA
ATC
Tars
147.5
39.3
41
*
E000007, ,
ATC
5.6
38.6
80
162
L40.8
ICD-10 Finland
Other psoriasis
143.6
38.3
40
*
D09AB01
ATC
zinc bandage without supplements; topical
13.1
31.8
31
25
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.8
30.1
75
177
XQ848
NOMESCO Finland
Dermatological photography
8.0
30.1
42
56
134
Kela drug reimbursment
General erythroderma
158.4
28.9
30
*
E000006, ,
ATC
4.7
28.4
71
168
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
+∞
25.2
24
*
L04AC10
ATC
secukinumab; parenteral
261.5
24.9
25
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
7.0
22.4
35
53
L04AC05
ATC
ustekinumab; parenteral
54.5
22.3
26
5
A07EC01
ATC
sulfasalazine; oral, rectal
3.9
22.2
70
197
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.6
21.8
160
741
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
6.8
21.2
34
53
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
+∞
21.0
20
*
L04AC18
ATC
risankizumab; parenteral
+∞
21.0
20
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.6
20.0
141
637
H02AB06
ATC
prednisolone; systemic
2.3
19.4
287
1795
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
18.9
18
*
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
+∞
18.9
18
*
L04AD01
ATC
ciclosporin; systemic
13.7
17.6
30
23
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.7
17.3
57
165
L04AC13
ATC
ixekizumab; parenteral
93.0
16.7
18
*
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
31.1
16.2
21
7
L04AA32
ATC
apremilast; oral
+∞
14.6
14
*
L04AA01
ATC
[U] ciclosporin
15.9
14.5
23
15
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.2
14.5
63
217
D07AA02
ATC
hydrocortisone; topical
2.5
14.4
108
496
J01FF01
ATC
clindamycin; systemic
2.1
13.6
167
940
D07XB01
ATC
flumetasone; topical
21.9
12.1
17
8
L04AA13
ATC
[U] leflunomide
5.7
11.7
22
40
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.7
11.6
68
276
WQ066, ,
NOMESCO Finland
+∞
11.5
11
*
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
+∞
11.5
11
*
L04AC16
ATC
guselkumab; systemic
122.5
11.5
12
*
L04AB01
ATC
etanercept; parenteral
10.9
11.4
21
20
A46
ICD-10 Finland
Erysipelas
2.4
10.8
80
363
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
10.3
231
1569
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.7
10.2
58
231
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
3.0
10.1
47
168
L88
ICPC
Rheumatoid/seropositive arthritis
3.9
9.4
28
75
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.8
9.3
239
1674
J01DB01
ATC
cefalexin; oral
2.1
9.3
457
3885
D07BC01
ATC
betamethasone and antiseptics; topical
2.3
8.9
68
312
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.2
8.4
74
361
S18
ICPC
Laceration/cut
1.7
8.3
236
1688
RJ421, ,
NOMESCO Finland
33.9
8.1
10
*
WW200
NOMESCO Finland
Immunization
4.2
8.1
21
51
D07AB01
ATC
clobetasone; topical
3.6
7.8
25
71
RJ411, ,
NOMESCO Finland
15.3
7.7
12
8
L04AX01
ATC
azathioprine; systemic
3.3
7.6
29
92
M07.2*L40.5
ICD-10 Finland
Psoriatic spondylitis
+∞
7.3
7
*
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
7.3
7
*
EB1AA
NOMESCO Finland
Intraoral radiographic dental examination
1.6
7.3
301
2344
E000004, ,
ATC
4.4
7.3
18
42
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
2.5
6.9
42
173
Z71.8
ICD-10 Finland
Other specified counselling
1.7
6.9
176
1208
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.5
6.7
44
188
SPAT1263
SPAT
Sampling
1.6
6.7
219
1600
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
2.0
6.6
74
395
N07BA03
ATC
varenicline; oral
2.8
6.5
33
124
D05AX05
ATC
tazarotene; topical
70.6
6.4
7
*
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
2.8
6.4
32
120
L04AB06
ATC
golimumab; parenteral
9.4
6.3
12
13
L40.1
ICD-10 Finland
Generalized pustular psoriasis
+∞
6.3
6
*
M073, L404,
ICD-10 Finland
+∞
6.3
6
*
EJA10
NOMESCO Finland
Biopsy of tongue or floor of mouth
6.4
6.2
15
24
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.6
6.0
288
2281
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
61
124
5.41
29.12
1.5
1.6
1.03
0.03
iu/ml
—
10
21
334
2032
2.67
26.89
12.0
5.3
2.81
2.82
%
0.04
323
1915
341
2116
2.64
26.03
12.0
5.4
28.46
28.52
%
0.04
329
2007
337
2094
2.60
25.41
11.5
5.1
57.30
56.87
%
0.33
326
1984
377
2530
2.60
23.25
13.4
8.2
4.13
4.02
e9/l
0.49
345
2222
28
14
21.01
19.25
1.9
1.1
7.56
9.97
ug/l
1.27
28
14
432
3277
2.55
17.62
5.7
3.7
11.92
10.67
mm/h
1.10
404
3025
429
3316
2.39
15.55
10.1
6.9
78.11
76.79
u/l
0.22
408
3117
176
1033
2.04
12.69
1.7
1.6
—
—
—
0
0
244
1759
1.70
8.31
2.6
2.2
75.29
75.45
nmol/l
0.03
225
1592
171
1139
1.73
7.65
4.8
3.8
21.31
9.80
mg/mmol
0.67
121
706
181
1235
1.70
7.37
3.9
2.8
87.74
105.61
e6/l
0.09
142
954
209
1485
1.66
7.27
3.1
3.0
34.11
32.16
u/l
0.32
197
1417
26
81
3.32
7.06
4.8
3.7
3.92
4.34
e9/l
0.48
26
81
15
20
7.68
6.94
2.6
1.5
20.47
34.27
%
—
10
15
26
83
3.24
6.80
4.9
4.3
57.38
57.63
%
0.03
26
83
164
1112
1.68
6.74
3.8
2.7
0.28
0.39
e6/l
0.54
126
837
203
1458
1.63
6.63
4.1
2.9
—
—
—
0
0
500
4536
2.26
6.55
18.4
12.0
18.21
21.37
mg/l
1.64
412
3497
157
1061
1.67
6.50
2.7
2.4
336.45
6411.49
umol/l
4.15
141
950
177
1237
1.64
6.41
4.1
3.1
7.33
7.94
mmol/l
0.96
151
1055
236
1771
1.59
6.36
11.4
10.9
1.14
1.18
inr
0.31
78
560
254
1960
1.56
5.94
6.1
6.3
1.21
1.22
mmol/l
0.43
215
1658
17
45
3.87
5.85
1.1
1.1
—
—
—
0
0
223
1700
1.53
5.36
5.4
4.6
35.82
36.30
g/l
0.68
208
1605
276
2202
1.51
5.34
5.7
5.9
10.38
11.20
umol/l
0.65
260
2090
77
450
1.83
5.24
6.4
7.1
103.47
104.22
mmol/l
0.56
77
450
298
2424
1.51
5.21
4.7
4.6
6.52
6.56
mmol/l
0.14
277
2234
128
864
1.63
5.19
3.4
2.3
5.75
6.46
e6/l
0.17
121
778
27
105
2.65
5.04
2.2
1.6
—
—
—
0
0
99
634
1.69
4.91
3.1
2.5
1.23
1.07
e6/l
0.20
60
346
119
808
1.61
4.68
1.4
1.3
20.40
33.14
iu/ml
0.82
26
264
489
4503
1.85
4.56
18.0
13.5
139.39
139.69
mmol/l
2.02
475
4380
93
597
1.67
4.56
1.8
1.8
—
—
—
0
0
466
4240
1.69
4.45
18.5
10.9
87.95
86.24
ml/min/173m2
0.94
413
3464
99
653
1.63
4.36
2.5
1.8
1.62
1.43
%
1.53
86
586
269
2197
1.44
4.29
4.4
3.3
0.00
0.01
estimate
0.50
62
417
93
607
1.64
4.27
3.2
2.7
2.74
2.67
e6/l
0.03
55
323
489
4520
1.81
4.26
18.1
13.5
3.96
3.95
mmol/l
0.05
473
4382
37
180
2.13
4.26
3.4
2.3
0.68
0.67
%
0.13
37
180
102
682
1.61
4.25
1.8
1.7
993.51
1204.15
nmol/l
1.66
82
526
266
2172
1.44
4.22
6.2
4.5
0.00
0.00
estimate
0.50
65
433
49
268
1.91
4.11
1.9
1.6
—
—
—
0
0
200
1555
1.45
4.10
2.1
1.9
95.98
96.44
pmol/l
0.05
118
822
56
321
1.83
4.07
4.5
3.4
2.01
1.91
mmol/l
0.09
50
259
264
2167
1.42
4.00
4.4
3.3
0.00
0.00
estimate
0.50
64
452
223
1782
1.43
3.90
5.4
5.6
1.21
1.22
mmol/l
0.57
204
1615
22
90
2.51
3.76
2.0
1.3
—
—
—
0
0
19
73
2.66
3.67
2.2
1.6
6443.67
11743.67
e6/l
0.69
12
51
61
371
1.73
3.65
1.9
2.2
0.22
0.22
g/l
0.26
53
349
110
780
1.51
3.52
1.4
1.3
1.66
11.29
u/ml
3.94
45
321
85
572
1.58
3.44
2.6
2.2
2.52
2.37
g/l
1.14
78
525
359
3161
1.40
3.36
3.8
2.9
55.35
43.11
u/l
1.75
332
2996
510
4828
1.90
3.35
18.2
9.1
29.79
26.82
u/l
1.74
501
4675
135
1010
1.45
3.29
2.7
2.0
3.36
2.98
mg/l
1.06
120
878
31
157
2.03
3.26
2.2
1.9
—
—
—
0
0
13
39
3.39
3.24
1.2
1.1
—
—
—
0
0
90
630
1.51
3.05
2.7
3.2
0.82
0.82
mmol/l
0.16
80
599
16
64
2.55
2.89
1.1
1.1
—
—
—
0
0
121
913
1.42
2.79
1.5
1.5
19.84
20.89
nmol/l
0.37
110
793
151
1191
1.37
2.67
2.1
2.0
186.76
229.47
u/l
0.23
143
1121
87
622
1.47
2.67
2.7
2.3
11.95
14.08
umol/l
1.57
81
573
27
141
1.96
2.65
1.3
1.1
—
—
—
0
0
7
15
4.71
2.60
1.0
1.1
1317.14
1812.80
miu/ml
—
7
15
27
142
1.95
2.60
1.3
1.1
—
—
—
0
0
59
390
1.58
2.59
5.4
3.0
—
—
—
0
0
16
68
2.39
2.58
1.8
1.4
—
—
—
0
0
13
50
2.64
2.55
3.2
2.7
4.28
3.99
mmol/l
0.78
13
50
13
50
2.64
2.55
3.2
2.7
104.46
105.40
mmol/l
0.24
13
50
98
727
1.42
2.48
3.4
3.6
759.88
367.40
ng/l
0.40
66
507
527
5097
2.09
2.40
29.3
17.7
135.69
136.42
g/l
0.57
522
5038
48
308
1.61
2.40
3.6
3.6
1.21
1.23
mmol/l
0.62
43
265
14
59
2.41
2.31
1.1
1.2
—
—
—
0
0
74
528
1.46
2.30
2.8
2.3
20.56
24.28
%
1.24
61
457
526
5090
2.01
2.29
29.2
17.7
256.96
253.82
e9/l
0.52
516
4987
140
1118
1.34
2.26
1.9
1.6
1.41
1.40
mmol/l
0.06
127
965
163
1331
1.32
2.25
3.2
2.4
52.91
60.28
u/l
1.08
149
1248
457
4292
1.41
2.23
4.4
4.0
5.98
5.83
mmol/l
1.37
415
3971
526
5095
1.98
2.20
29.2
17.6
4.48
4.54
e12/l
1.58
515
4983
57
390
1.52
2.18
3.4
2.3
25.29
158.89
u/l
0.55
51
326
127
1009
1.34
2.11
1.7
1.7
1.18
1.00
mg/l
0.28
99
757
18
89
2.06
2.08
1.7
1.8
—
—
—
0
0
26
147
1.81
2.06
2.1
1.7
—
—
—
0
0
59
413
1.48
2.03
5.7
8.8
5.04
5.13
kpa
0.26
53
395
59
413
1.48
2.03
5.6
8.8
12.72
12.49
kpa
0.08
53
397
19
97
1.99
2.02
2.5
2.2
292.16
117.00
ug/min
0.30
11
57
58
407
1.48
1.98
1.7
1.9
342.02
372.59
nmol/l
0.57
50
375
18
92
1.99
1.92
1.7
1.7
—
—
—
0
0
524
5088
1.81
1.88
29.1
17.7
40.02
40.53
%
0.96
498
4819
106
834
1.34
1.88
1.8
1.6
423.05
11480378.07
pmol/l
0.50
92
723
8
28
2.88
1.87
1.1
1.1
296.00
145.92
iu/ml
—
8
28
358
3286
1.26
1.81
3.4
3.3
—
—
—
0
0
101
795
1.33
1.79
2.1
2.1
—
—
—
0
0
441
4157
1.32
1.78
4.9
4.6
1.80
2.11
mu/l
0.55
403
3856
36
233
1.58
1.78
1.5
1.4
—
—
—
0
0
14
67
2.12
1.77
1.3
1.8
—
—
—
0
0
92
716
1.34
1.76
2.1
2.0
—
—
—
0
0
9
36
2.52
1.74
1.4
1.6
—
—
—
0
0
141
1166
1.28
1.74
4.7
3.5
0.00
0.00
estimate
0.80
63
423
65
479
1.41
1.73
2.5
2.5
6.54
8.63
umol/l
0.74
56
412
197
1702
1.25
1.67
4.9
3.3
—
—
—
0
0
57
413
1.42
1.67
5.8
8.9
0.53
1.15
mmol/l
0.37
42
331
123
1007
1.29
1.64
2.3
2.2
—
—
—
0
0
180
1545
1.25
1.61
4.0
3.3
84.45
36.96
ng/l
0.45
111
965
28
175
1.63
1.61
1.2
1.4
—
—
—
0
0
11
221
0.49
1.59
4.8
1.8
1.24
3.75
mg/l
—
6
164
424
3998
1.27
1.56
6.7
5.1
39.96
39.11
mmol/mol
0.88
397
3761
132
1097
1.27
1.56
1.3
1.2
1.15
1.99
u/ml
0.69
33
310
6
21
2.88
1.51
1.8
3.5
73.17
90.62
nmol/l
—
6
21
28
179
1.59
1.49
5.7
3.2
25.21
24.94
mmol/l
0.23
28
174
17
94
1.83
1.49
1.1
1.2
—
—
—
0
0
14
253
0.54
1.48
2.5
2.4
14.36
41.68
u/ml
1.95
14
243
34
228
1.52
1.48
3.5
3.2
1.64
1.68
mmol/l
0.02
26
169
372
3469
1.23
1.44
4.0
3.9
14.61
14.60
pmol/l
0.05
335
3174
5
16
3.14
1.44
1.4
1.3
—
—
—
0
0
6
22
2.75
1.44
6.3
2.9
418.00
535.18
u/ml
—
6
22
9
39
2.33
1.43
1.2
1.2
—
—
—
0
0
229
2037
1.21
1.43
2.6
2.5
—
—
—
0
0
13
67
1.96
1.39
1.8
1.7
—
—
—
0
0
13
67
1.96
1.39
1.8
1.7
—
—
—
0
0
464
4444
1.30
1.37
5.2
4.0
4.69
4.71
mmol/l
0.12
432
4182
0
37
0.00
1.35
0.0
1.5
—
20.42
—
0
32
9
42
2.16
1.34
1.1
2.0
—
—
—
0
0
24
152
1.61
1.34
1.3
1.9
—
—
—
0
0
37
260
1.45
1.31
2.5
3.0
169.70
177.89
ng/l
0.03
30
229
9
43
2.11
1.31
1.1
1.7
—
—
—
0
0
9
43
2.11
1.31
1.1
1.7
—
—
—
0
0
9
43
2.11
1.31
1.1
1.7
—
—
—
0
0
229
2054
1.20
1.28
3.4
2.8
99.08
108.43
ug/l
0.36
216
1920
54
409
1.36
1.26
1.7
1.8
—
—
—
0
0
17
100
1.72
1.25
1.6
1.2
—
—
—
0
0
6
25
2.42
1.24
3.0
1.9
—
1224630.00
iu/ml
—
0
5
15
85
1.79
1.24
1.5
2.0
—
—
—
0
0
15
86
1.77
1.20
3.2
4.1
17.40
29.67
mg/l
—
10
58
29
199
1.48
1.17
1.5
1.7
—
—
—
0
0
12
65
1.87
1.14
1.4
1.1
—
—
—
0
0
7
30
2.35
1.12
1.3
1.2
—
—
—
0
0
445
4268
1.23
1.11
4.8
3.6
1.36
1.28
mmol/l
1.12
413
3991
118
1006
1.22
1.11
3.2
3.1
1810.52
1164.64
ng/l
0.33
101
854
39
287
1.39
1.10
1.3
1.3
—
—
—
0
0
19
120
1.60
1.10
1.4
2.0
1.94
6.20
iu/l
—
7
45
14
81
1.75
1.10
1.1
1.1
6.09
2.21
u/ml
—
9
39
155
1359
1.20
1.09
2.6
3.0
2.34
2.35
mmol/l
0.73
138
1220
15
89
1.70
1.08
2.9
2.3
8.72
8.13
kpa
1.24
15
89
52
403
1.32
1.07
1.7
1.7
—
—
—
0
0
7
33
2.14
1.06
1.6
2.9
—
—
—
0
0
7
33
2.14
1.06
1.1
1.4
—
—
—
0
0
5
22
2.28
1.03
1.2
1.4
5.46
6.48
mmol/l
—
5
22
9
49
1.85
0.99
1.1
1.8
—
—
—
0
0
9
52
1.74
0.92
1.4
1.6
—
—
—
0
0
13
206
0.62
0.90
2.5
1.9
—
—
—
0
0
8
43
1.87
0.87
2.3
1.6
—
—
—
0
0
8
43
1.87
0.87
2.3
1.6
—
—
—
0
0
11
179
0.61
0.86
1.5
1.4
—
—
—
0
0
11
179
0.61
0.86
1.5
1.4
—
—
—
0
0
12
72
1.68
0.85
1.3
1.2
—
—
—
0
0
15
96
1.58
0.85
1.3
1.3
—
—
—
0
0
11
178
0.61
0.84
1.5
1.4
—
—
—
0
0
11
178
0.61
0.84
1.5
1.4
—
—
—
0
0
23
164
1.42
0.81
1.5
1.5
—
—
—
0
0
18
122
1.49
0.81
1.0
1.3
—
2.57
—
0
14
54
656
0.80
0.79
2.8
2.8
0.63
0.72
ug/l
0.36
36
399
18
124
1.47
0.76
1.0
1.3
—
7.32
—
0
20
9
54
1.68
0.75
2.4
1.7
—
—
—
0
0
21
150
1.42
0.74
1.9
1.7
—
—
—
0
0
5
25
2.01
0.73
1.6
1.8
—
—
—
0
0
5
25
2.01
0.73
3.2
3.1
34560.00
35216.20
ug/l
—
5
25
5
25
2.01
0.73
1.0
1.8
—
—
—
0
0
5
25
2.01
0.73
1.0
1.8
—
—
—
0
0
7
39
1.81
0.72
2.3
2.2
—
—
—
0
0
31
238
1.32
0.72
3.1
2.3
5593.84
3197.60
u/l
—
10
106
12
76
1.59
0.72
1.3
1.2
—
—
—
0
0
12
76
1.59
0.72
1.3
1.2
—
—
—
0
0
464
4517
1.19
0.70
5.3
4.4
2.81
2.82
mmol/l
0.07
432
4226
9
59
1.53
0.68
1.4
1.3
—
—
—
0
0
7
42
1.68
0.68
1.1
1.0
—
—
—
0
0
35
277
1.28
0.67
5.2
3.5
123.73
75.69
ng/l
1.04
30
249
7
43
1.64
0.67
1.0
1.1
—
—
—
0
0
18
128
1.42
0.66
1.2
1.3
—
—
—
0
0
5
28
1.79
0.66
1.0
1.2
—
—
—
0
0
5
29
1.73
0.64
1.4
1.3
3.36
1.89
mmol/l
—
5
29
10
63
1.60
0.62
2.3
1.6
—
—
—
0
0
454
4424
1.16
0.61
4.9
4.0
1.45
1.46
mmol/l
0.42
424
4151
40
327
1.24
0.60
3.7
2.6
66.91
69.84
ml/min/173m2
0.23
22
140
39
318
1.24
0.60
2.5
2.3
7.18
7.74
ug/l
0.11
31
286
10
64
1.57
0.59
1.6
2.7
—
1032.00
—
0
6
16
219
0.72
0.58
1.3
1.4
—
—
—
0
0
108
969
1.14
0.58
4.5
3.4
1.02
1.02
kg/l
0.05
23
134
18
132
1.38
0.57
1.0
1.3
—
2.27
—
0
6
6
36
1.67
0.57
1.5
1.8
—
—
—
0
0
6
37
1.63
0.55
1.0
1.1
—
—
—
0
0
9
60
1.51
0.54
1.4
1.4
—
—
—
0
0
9
60
1.51
0.54
1.4
1.4
—
—
—
0
0
6
38
1.59
0.54
3.0
3.7
—
—
—
0
0
14
191
0.73
0.51
1.5
1.5
—
—
—
0
0
13
94
1.39
0.46
1.0
1.2
—
1.00
—
0
5
11
78
1.42
0.43
1.5
1.2
—
—
—
0
0
5
33
1.52
0.41
1.0
1.4
—
—
—
0
0
5
33
1.52
0.41
1.4
1.2
—
0.32
u/ml
—
0
17
5
33
1.52
0.41
1.2
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
8
59
1.36
0.41
1.5
1.4
—
—
—
0
0
8
60
1.34
0.40
1.5
1.3
—
—
—
0
0
8
60
1.34
0.40
1.5
1.4
—
—
—
0
0
43
372
1.17
0.40
4.0
4.4
3.22
18.49
ug/l
0.73
32
305
13
97
1.35
0.40
1.0
1.2
—
—
—
0
0
5
35
1.43
0.39
1.2
1.9
—
—
—
0
0
9
66
1.37
0.38
1.1
1.2
127.22
117.28
%
—
9
61
81
889
0.90
0.38
3.8
4.1
24.96
20.81
%
0.82
32
384
5
37
1.35
0.37
1.6
1.8
—
—
—
0
0
31
363
0.85
0.36
1.1
1.2
92.26
165.95
iu/ml
1.31
13
152
9
71
1.27
0.36
1.1
1.1
—
—
—
0
0
22
181
1.22
0.35
1.3
1.4
198.48
255.02
miu/ml
0.35
11
90
10
73
1.38
0.34
2.3
1.6
—
—
—
0
0
6
45
1.34
0.34
1.5
3.1
22.67
53.16
u/ml
—
6
45
21
173
1.22
0.33
2.4
1.7
—
—
—
0
0
28
326
0.85
0.32
1.6
1.5
—
—
—
0
0
12
153
0.78
0.31
1.7
1.6
—
—
—
0
0
14
111
1.27
0.30
1.4
3.3
—
2.09
—
0
16
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
102
1.28
0.30
3.2
3.6
0.29
0.37
u/ml
—
8
59
29
250
1.17
0.30
1.2
1.3
36.50
25.78
iu/l
0.67
23
213
7
56
1.25
0.29
1.9
2.2
—
—
—
0
0
30
260
1.16
0.29
1.1
1.0
—
—
—
0
0
7
57
1.23
0.29
1.6
1.6
—
—
—
0
0
5
39
1.28
0.23
1.4
1.2
147.68
186.38
pmol/l
—
5
39
76
711
1.08
0.22
2.9
2.7
2.44
2.44
mmol/l
0.06
69
629
48
440
1.10
0.22
2.4
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
9.57
—
0
6
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
2.2
—
2.42
—
0
6
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
6
48
1.25
0.20
1.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
3.9
—
—
—
0
0
0
14
0.00
0.20
0.0
3.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
10
122
0.82
0.19
1.4
1.8
39.65
38.08
g/l
—
10
113
12
142
0.84
0.17
1.3
1.9
2.95
2.93
g/l
0.03
12
133
14
120
1.17
0.16
2.0
2.8
—
—
—
0
0
11
92
1.20
0.16
1.5
1.5
—
—
—
0
0
15
130
1.16
0.15
1.3
1.1
—
—
—
0
0
9
78
1.16
0.15
1.0
1.1
—
—
—
0
0
53
501
1.06
0.13
4.5
4.1
31.06
31.69
%
0.17
35
346
51
483
1.06
0.12
14.0
5.9
—
—
—
0
0
87
838
1.05
0.12
1.6
1.4
—
—
—
0
0
21
191
1.10
0.12
1.3
1.4
—
—
—
0
0
37
348
1.07
0.11
2.2
1.8
—
—
—
0
0
108
1111
0.97
0.10
4.6
4.4
1.36
2.09
ug/l
1.58
95
996
15
135
1.11
0.09
1.6
1.7
—
—
—
0
0
5
48
1.04
0.09
1.0
1.1
—
—
—
0
0
6
56
1.07
0.08
1.0
1.0
—
—
—
0
0
5
62
0.80
0.08
1.0
1.1
—
—
—
0
0
10
88
1.14
0.08
1.5
1.8
—
—
—
0
0
13
118
1.10
0.07
1.5
1.5
—
—
—
0
0
10
111
0.90
0.06
1.4
1.9
0.00
0.00
g/l
—
10
106
18
171
1.05
0.03
1.3
1.4
1.29
1.20
g/l
0.71
18
163
50
491
1.02
0.02
1.7
1.6
—
—
—
0
0
11
117
0.94
0.01
1.4
1.9
0.05
0.04
g/l
0.01
11
112
10
104
0.96
0.00
1.0
1.3
—
—
—
0
0
15
149
1.01
0.00
1.3
1.9
7.91
7.37
g/l
0.56
15
140
15
149
1.01
0.00
1.3
1.9
—
—
—
0
0
15
149
1.01
0.00
1.3
1.9
3.71
3.67
g/l
0.06
15
140
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
5
53
0.94
0.00
1.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
1.28
—
0
7
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
8
82
0.98
-0.00
1.5
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
11.28
—
0
5
0
5
0.00
-0.00
0.0
3.0
—
0.60
—
0
5
5
54
0.93
-0.00
1.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PSORI_GUTTATE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PSORI_GUTTATE | 1.255 [1.02, 1.54] | 0.032 |
| Birth year | 0.994 [0.99, 1.0] | 0.2 |
During the follow-up period (1.1.1998 — 31.12.2019), 164 out of 1925 females with L12_PSORI_GUTTATE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PSORI_GUTTATE | 1.695 [1.38, 2.08] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.01 |
During the follow-up period (1.1.1998 — 31.12.2019), 209 out of 1420 males with L12_PSORI_GUTTATE died.
Mortality risk
Mortality risk for people of age
years, who have L12_PSORI_GUTTATE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.107% | 0.352% |
| 5 | 0.745% | 1.989% |
| 10 | 1.799% | 4.954% |
| 15 | 3.345% | 9.073% |
| 20 | 5.875% | 14.936% |
Relationships between endpoints
↥Index endpoint: L12_PSORI_GUTTATE – Guttate psoriasis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data